17D yellow fever vaccine

The 17D yellow fever vaccine is a live attenuated viral vaccine developed from the 17D strain of the yellow fever virus. It is used for active immunization to prevent yellow fever—a potentially fatal viral hemorrhagic disease endemic in parts of Africa and South America. The most widely used substrains are 17D-204 and 17DD; both are considered to have equivalent safety and efficacy profiles[2][8]. The mechanism of action involves initial infection at the injection site with limited replication and spread of the attenuated virus, leading to robust humoral immune responses (neutralizing antibodies) that confer long-lasting protection—typically lifelong after a single dose in most healthy individuals[1][2][7]. Immunity develops within ten days in about 90% of recipients and within fourteen days in nearly all recipients[1]. The World Health Organization recommends routine immunization for residents or travelers to endemic areas. The primary developer was Max Theiler at Rockefeller Foundation Laboratories in the late 1930s. Modern manufacturing uses pathogen-free chicken embryos as substrate[1][2].

Brand names

YF-VAXStamaril

Other names

yellow fever vaccinelive attenuated yellow fever vaccineYF-17D vaccineYF17D vaccineYF 17D vaccine